DSpace About DSpace Software 日本語
 

GINMU >
01 奈良県立医科大学 >
011 医学部 >
0112 紀要 >
01121 Journal of Nara Medical Association >
Vol.46 No.1 >

Please use this identifier to cite or link to this item: http://hdl.handle.net/10564/795

Title: RAYNAUD'S SYNDROME IMPROVED BY THE INTRAVENOUS ADMINISTRATION OF A THROMBOXANE SYNTHETASE INHIBITOR
Authors: Tsuchihashi, Masayuki
Tsunoda, Shigeru
Kitaoka, Soichi
Morita, Yasuhiro
Yumura, Fumitoshi
Yoshida, Kazumasa
Hayashi, Masafumi
Ariyoshi, George
Dohi, Kazuhiro
Keywords: prostacyclin
Raynaud's syndrome
sodium ozagrel
thromboxane synthetase inhibitor
thromboxane A₂
Issue Date: 28-Feb-1995
Publisher: 奈良医学会
Citation: 奈良医学雑誌 Vol.46 No.1 p.25-30
Abstract: A 66-year-old man with multiple cerebral infarctions was treated with sodium ozagral ; this was associated with an improvement in his Raynaud's syndrome attributable to vibration-induced white finger disease. Sodium ozagrel selectively inhibits thromboxane synthetase, reducing thromboxane A₂ (TXA₂) and also slightly increasing prostacyclin (PGI₂) ; this leads to vasodilatation and the inhibition of platelet aggregation. An imbalance between TXA₂ and PGI₂ caused by vascular endothelial injury is thought to cause Raynaud's phenomenon. Sodium ozagrel appears to improve the symptoms of Raynaud's syndrome by relatively increasing PGI₂, thus correcting the imbalance. Ozagrel, which currently is being used to treat cerebral thrombosis and bronchial asthma, as well as to improve vasospasm following subarachnoid hemorrhage, also may provide effective relief in patients with Raynaud's syndrome.
URI: http://hdl.handle.net/10564/795
ISSN: 04695550
13450069
Appears in Collections:Vol.46 No.1

Files in This Item:

File Description SizeFormat
025-030p.RAYNAUD'S_SYNDROME_IMPROVED_BY_THE_INTRAVENOUS_ADMINISTRATION.pdf1.21 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2010  Duraspace - Feedback